Paclitaxel/carboplatin (PC) plus bevacizumab/erlotinib as first-line treatment for patients (pts) with carcinoma of unknown primary (CUP) site

被引：2
|
作者：
Greco, F. A.
Burris, H. A., III
Spigel, D. R.
Thompson, D. S.
Waterhouse, D. M.
Hanson, S.
Vazquez, E. R.
Hainsworth, J. D.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Oncol Hematol Care Inc, Cincinnati, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.4607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4607
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site
    Hainsworth, John D.
    Spigel, David R.
    Thompson, Dana S.
    Murphy, Patrick B.
    Lane, Cassie M.
    Waterhouse, David M.
    Naot, Yuval
    Greco, F. Anthony
    [J]. ONCOLOGIST, 2009, 14 (12): : 1189 - 1197
  • [2] Paclitaxel/Carboplatin With or Without Belinostat as Empiric First-Line Treatment for Patients With Carcinoma of Unknown Primary Site: A Randomized, Phase 2 Trial
    Hainsworth, John D.
    Daugaard, Gedske
    Lesimple, Thierry
    Huebner, Gerdt
    Greco, F. Anthony
    Stahl, Michael J.
    Bueschenfelde, Christian Meyer Zum
    Allouache, Djelila
    Penel, Nicolas
    Knoblauch, Poul
    Fizazi, Karim S.
    [J]. CANCER, 2015, 121 (10) : 1654 - 1661
  • [3] Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP
    Folprecht, Gunnar
    Trautmann, Karolin
    Stein, Alexander
    Huebner, Gerdt
    Stahl, Michael
    Kasper, Stefan
    Kretzschmar, Albrecht
    Koehne, Claus-Henning
    Gruenwald, Viktor
    Hofheinz, Ralf-Dieter
    Schuette, Katharina
    Loeffler, Harald
    Bokemeyer, Carsten
    Kraemer, Alwin
    [J]. BRITISH JOURNAL OF CANCER, 2021, 124 (04) : 721 - 727
  • [4] Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP
    Gunnar Folprecht
    Karolin Trautmann
    Alexander Stein
    Gerdt Huebner
    Michael Stahl
    Stefan Kasper
    Albrecht Kretzschmar
    Claus-Henning Köhne
    Viktor Grünwald
    Ralf-Dieter Hofheinz
    Katharina Schütte
    Harald Löffler
    Carsten Bokemeyer
    Alwin Krämer
    [J]. British Journal of Cancer, 2021, 124 : 721 - 727
  • [5] Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
    Ilhan, Yusuf
    Tatli, Ali Murat
    Teker, Fatih
    Onder, Arif Hakan
    Kose, Fatih
    Geredeli, Caglayan
    Karaagac, Mustafa
    Kaplan, Muhammet Ali
    Inanc, Mevlude
    Aydin, Sabin Goktas
    Kargi, Aysegul
    Arak, Haci
    Ozturk, Banu
    Besen, Ali Ayberk
    Selvi, Oguzhan
    Korkmaz, Mustafa
    Oruc, Zeynep
    Bozkurt, Oktay
    Bilici, Ahmet
    Bayram, Selami
    Dae, Shute Ailia
    Ozdogan, Mustafa
    Coskun, Hasan Senol
    Goksu, Sema Sezgin
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (04) : 502 - 507
  • [6] Tolerability of carboplatin, paclitaxel and erlotinib as first-line treatment of ovarian cancer.
    Blank, SV
    Curtin, JP
    Goldman, NA
    Fusco, E
    Lesko, Z
    Hochster, H
    Runowicz, CD
    Wadler, S
    Muggia, FM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 467S - 467S
  • [7] Maintenance erlotinib (E) following first-line treatment with docetaxel, carboplatin and erlotinib in patients with ovarian carcinoma
    Vasey, P. A.
    Paul, J.
    Rustin, G.
    Wilson, R.
    Guastalla, J.
    Pujade-Lauraine, E.
    Gore, M.
    Gabra, H.
    Carty, K.
    Kaye, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
    K Yonemori
    M Ando
    M Yunokawa
    T Hirata
    T Kouno
    C Shimizu
    K Tamura
    N Katsumata
    A Hirakawa
    K Matsumoto
    Y Yamanaka
    H Arioka
    Y Fujiwara
    [J]. British Journal of Cancer, 2009, 100 : 50 - 55
  • [9] Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
    Yonemori, K.
    Ando, M.
    Yunokawa, M.
    Hirata, T.
    Kouno, T.
    Shimizu, C.
    Tamura, K.
    Katsumata, N.
    Hirakawa, A.
    Matsumoto, K.
    Yamanaka, Y.
    Arioka, H.
    Fujiwara, Y.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 100 (01) : 50 - 55
  • [10] WHAT IS THE BEST SCHEDULE FOR PACLITAXEL plus CARBOPLATIN AS FIRST-LINE TREATMENT IN PRIMARY OVARIAN CANCER?
    Sehouli, J.
    Oskay-Oezcelik, G.
    Lichtenegger, W.
    [J]. ANTICANCER RESEARCH, 2004, 24 (5D) : 3628 - 3628
12345